Effects of metabolic syndrome and its components on serum HBsAg levels in patients with chronic hepatitis B

doi:10.19871/j.cnki.xfcrbzz.2023.01.006

Abstract

Abstract: Objective To explore the effects of metabolic syndrome and its components on serum HBsAg levels in patients with chronic hepatitis B, so as to provide ideas for the subsequent clinical cure of chronic hepatitis B patients with metabolic syndrome. Method A retrospective analysis of 415 patients with chronic hepatitis B who were admitted to Shanxi Bethune Hospital from May 2019 to September 2020. They were divided into chronic hepatitis B group and chronic hepatitis B combined with metabolic syndrome group according to whether they were complicated with metabolic syndrome. The general data, biochemical parameters, virological parameters, and liver transient elasticity were collected. Non-parametric rank sum test, chi-square test and multiple linear regression were used to analyze the effects of metabolic syndrome and its components on serum HBsAg levels in patients with chronic hepatitis B. Result A total of 415 patients were included in this study, including 247 patients (59.50%) in CHB group and 168 patients (40.50%) in CHB combined with MetS group. The results of multiple linear regression showed that blood glucose and triglyceride had statistically significant effects on serum HBsAg level (t=-3.25, P=0.001; t=2.25, P=0.025), while blood pressure and waist circumference had no statistically significant effects on serum HBsAg level. Conclusion Blood glucose negatively predicted serum HBsAg level in CHB patients, triglyceride positively predicted serum HBsAg level in CHB patients, but blood pressure and waist circumference did not affect the level of HBsAg.

Key words: Chronic hepatitis B, Metabolic syndrome, Hepatitis B surface antigen

CLC Number:

R58
R512.6+2

Wang Hongxia, Wang Yan, Duan Ruixian, Zhang Jianwei, Ren Yuan. Effects of metabolic syndrome and its components on serum HBsAg levels in patients with chronic hepatitis B[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(1): 31-34.

References

[1] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中国医学前沿杂志(电子版), 2019, 11(12):51-77.
[2] ZHOU K,CONTAG C,WHITAKER E,et al.Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: A systematic review and pooled meta–analyses[J]. Lancet Gastroenterol Hepatol, 2019, 4(3): 227–238.
[3] YEO YH, HO HJ, YANG HI, et al.Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: A systematic review and Meta–analysis[J]. Gastroenterology, 2019, 156(3):635–646.
[4] LU J, WANG L, LI M, et al.2010 China Noncommunicable Disease Surveillance Group. Metabolic Syndrome Among Adults in China: The 2010 China Noncommunicable Disease Surveillance[J]. J Clin Endocrinol Metab, 2017, 102(2): 507-515.
[5] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409.
[6] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 中华传染病杂志, 2019, (8): 461-472.
[7] PETER J, SYLVIA D, JAN F, et al.Association between hepatitis B and metabolic syndrome:Current state of the art[J]. World J Gastroenterol, 2016, 63(1): 155-164.
[8] 吴琦琦, 马燕, 王晓波, 等. 代谢综合征对慢性乙型肝炎患者显著肝纤维化的影响[J]. 临床肝胆病杂志, 2018, 34(12): 2572-2577.
[9] ZHANG JB, LIN SZ, JIANG DX, et al.Chronic hepatitis B and non-alcoholic fatty liver disease: Conspirators or competitors?[J]. Liver Inter, 2020, 40(3): 496-508.
[10] LIM CT, KUMAR R.Hepatitis B and concomitant hepatic steatosis[J]. Ann Transl Med, 2017, 5: 38.
[11] FELDSTEIN AE, CANBAY A, ANGULO P, et al.Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis[J]. Gastroenterology, 2003, 125(2): 437-443.
[12] ZHANG Z, PAN Q, DUAN XY, et al.Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model[J]. J Gastroenterol Hepatol, 2012, 27(12): 1858-1864.
[13] HSUEH RC, WU WJ, LIN CL, et al.Impact of PNPLA3 p.I148M and Hepatic Steatosis on Long-Term Outcomes for Hepatocellular Carcinoma and HBsAg Seroclearance in Chronic Hepatitis B[J]. J Hepatocell Carcinoma, 2022, 11(9): 301-313.
[14] HU D, WANG H, WANG H,et al.Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model[J]. Hepatol Int, 2018, 12(5): 438-446.
[15] HSIANG J, WONG GL, CHAN HL, et al.Editorial: metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B--authors' reply[J]. Aliment Pharmacol Ther, 2014, 40(8): 983.
[16] 杨玲玲, 何金秋, 张雪珍. 乙型肝炎肝硬化合并2型糖尿病预后分析[J]. 中华传染病杂志, 2016, 34(1): 10-14.
[17] 柴艳云, 张锦前, 凌伟, 等. 慢性乙型肝炎伴发代谢综合征影响因素分析[J/CD]. 中华实验和临床感染病杂志(电子版), 2009, 3(1): 50-55.
[18] PETTA S, MACALUSO FS, BARCELLONA MR, et al.Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases[J]. PLoS One, 2012, 7(12): e51165.
[19] MARINO L, JORNAYVAZ FR.Endocrine causes of nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2015, 21(39): 11053-11076.
[20] LIU J, LEE MH, BATRLA-UTERMANN R, et al.A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection[J]. J Hepatol, 2013, 58(5): 853-860.
[21] MAK LY, HUI RW, FUNG J, et al.Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B[J]. J Hepatol, 2020, 73(4): 800-806.